Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05799521 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Nasal Treatment for COVID-19

Study acronym: COVD-TX
StatusActive, Not Recruiting
PhasePhase 2
Started2023-06-27
View on ClinicalTrials.gov ↗

Amendment history

2026-05-26
Study Status, Study Design, Contacts/Locations v11
Trial status changed: Recruiting → Active, Not Recruiting
Enrollment reduced: 40 → 24 participants
Study sitesdetails revised at 1 of 1 site
2026-05-12
Study Status v10
Primary completion date2026-03-30→2027-03-30
Completion date2026-03-30→2027-03-30
2025-12-18
Study Status, Oversight, Conditions, Study Design, Arms and Interventions, Outcome Measures, Eligibility v9
Study arms2→4
Eligibility criteria+463 characters
COVID-19 PARTICIPANTS Inclusion Criteria: Subjects, 18 and above, with mild COVID- [...] res OSCI ≥ 3 (Objective Structured Clinical Exam) Pregnancy Inability to follow commands or perform study procedures including spirometry, coordinated inhalation of study medication HEALTHY CONTROLS Inclusion Criteria: Subjects, 18 and above, without mild COVID-19 upper respiratory tract infection symptoms negative rapid COVID-19 test No known medical proble [...] Inability to follow commands or perform study procedures inc [...]
Secondary endpointsdetails revised at 1 of 2 entries
2025-10-21
Study Status v8
Re-verified, no change to tracked fields
2025-04-30
Study Status, Contacts/Locations v7
Primary completion date2025-03-30→2026-03-30
Completion date2025-03-30→2026-03-30
Study sitescontacts updated at 1 of 1 site
Show 6 earlier versions
2025-02-24
Study Status, Eligibility v6
Eligibility criteria+10 characters
[...] dy procedures OSCI ≥ 3 (Objective Structured Clinical Exam) Pregnancy Inability to follow commands or perform study procedures inc [...]
2024-10-24
Study Status, Oversight, Outcome Measures v5
Secondary endpoints1 to 2 entries
SurveyChange assessmentin SARS-CoV-2 Levels Change in nasal pH
Primary endpoints1 to 3 entries
MeasurementChange of Clinical Respiratory Viral panels andin SARS-CoV-2 Levels Change in SNOT-22 score Change in SNOT-22 score
2024-04-24
Study Status v4
Primary completion date2024-03-30→2025-03-30
Completion date2024-03-30→2025-03-30
2023-08-23
Study Status v3
Primary completion date2023-12-31→2024-03-30
Completion date2023-12-31→2024-03-30
2023-07-05
Study Status v2
Start date2023-04-27→2023-06-27
2023-05-22
Not Yet Recruiting→Recruiting Study Status, Study Design, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
PhaseEarly Phase 1→Phase 2
Start dateestimated 2023-04-20→confirmed 2023-04-27
Study sites0→1
2023-04-04
Original filing
The goal of this study is to test an investigational new inhaled medication called Optate.
Trial Details
NCT Number NCT05799521
Lead Sponsor Indiana University
Conditions COVID-19, Healthy
Enrollment 24 participants
Start Date 2023-06-27
Primary Completion 2027-03-30 (estimated)
Study Completion 2027-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-28